Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival

Table 3 Uni- and multivariate analysis of the factors associated with transplantation outcome

Covariate	Univariate analysis			Multivariate analysis
	HR	95%CI	P	HR	95%CI	P
OS > 700 days
Conditioning BU/CY2 vs. TBI/CY	1.22	0.24–6.13	0.81
MRD (N vs P)	8.11	0.84–78.08	0.07	1.00	0.08–12.18	0.97
Age (< 35y vs. ≥ 35y)	2.55	0.51–12.64	0.25
Blood type Match & minor vs. major & bid	1.21	0.22–6.62	0.83
F/M vs. Others	0.33	0.07–1.62	0.17	0.32	0.06–1.76	0.19
Transplantation time 2006–16 vs. 2017–20	0.55	0.10–3.06	0.49
CR1 vs. ≥ CR2	6.61	1.21–36.19	0.03	8.32	1.30–53.11	0.03
WBC (× 10⁹/l) < 30 vs. ≥ 30	0.59	0.07–5.02	0.63
Cytogenetical prognosis Good vs. poor	2.30	0.42–12.58	0.34
UCBT vs MST	4.43	0.81–24.20	0.09	7.40	1.12–48.93	0.04
DFS
Conditioning BU/CY2 vs. TBI/CY	1.86	1.13–3.11	0.02	1.99	1.00–3.95	0.05
MRD (N vs. P)	1.84	0.73–4.59	0.19	1.63	0.56–4.73	0.37
Age(< 35y vs ≥ 35y)	0.90	0.52–1.56	0.71
Blood type Match & minor vs major & bid	1.56	0.94–2.60	0.09	1.64	0.96–2.80	0.07
F/M vs. others	0.93	0.53–1.65	0.81
Transplantation time 2006–16 vs. 2017–20	0.68	0.41–1.13	0.13	0.87	0.43–1.75	0.70
Response to induction Good vs. poor	1.42	0.61–3.30	0.41
CR1 vs. ≥ CR2	2.40	1.45–3.99	< 0.001	2.34	1.38–3.97	0.002
WBC (× 10⁹/l) < 30 vs. ≥ 30	1.16	0.67–2.00	0.61
Cytogenetical prognosis Good vs. poor	0.77	0.46–1.28	0.31
UCBT vs. MST	1.07	0.62–1.85	0.82	1.05	0.58–1.90	0.86

BU Busulfan, CAR-T Chimeric antigen receptor T-cell, CR Complete remission, CsA Cyclosporin A, CY Cyclophosphamide, GVHD Graft-versus-host disease, HSCT Hematopoietic stem cell transplant, MMF Mycophenolate mofetil, MRD Minimal residual disease, MTX Methotrexate, TBI Total body irradiation, TNC Total nucleated cells, WBC White blood cell

ISSN: 1757-6512